ClinicalTrials.gg

Psoriasis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,030 studies for Psoriasis across more than 10 countries. 276 are recruiting or about to start. 1,782 of them are mainly about Psoriasis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Arthritis, Psoriatic too: 2,503 studies, 378 open.

ClinicalTrials.gov finds 2,582 studies for Psoriasis. How that becomes 2,030 here

This page counts the studies the registry files under Psoriasis, and those it files under no condition that list Psoriasisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,582Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −468Filed under a narrower condition, counted on its own pageArthritis, Psoriatic 468
  3. −56List Psoriasis as a condition, but the registry did not file them under itMost often written as “Plaque Psoriasis” (20), “Psoriasis Vulgaris” (16), and “Chronic Plaque Psoriasis” (4). The registry filed them under other conditions only, most often Pruritus (11) and Skin Diseases (8).
  4. −28Match it another way26 name it in the title and 2 in a keyword.
  5. 2,030The count on this page559 of them list Psoriasis in their own words; the registry filed them under no condition.

Status

Completed
1,375
Recruiting
173
Status unknown
152
Terminated
107
Not yet recruiting
93
Active, not recruiting
66

Phase

Phase 2
444
Phase 3
425
Phase 1
270
Phase 4
261
Early Phase 1
22

Where

United States
764
Canada
303
Germany
299
China
206
France
185
Poland
166

Who develops what

Add Psoriasis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 63 programs from 46 companies, 60 with this as their studies’ main aim; 22 with a live phase 3 study; 20 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Hansoh Pharmaceutical Group and Sino Biopharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AdalimumabRecent, repeated
Evidence
  • NCT06640517 · Biocad · Phase 3 · live · comparator · “Adalimumab” · registered Oct 2024
  • NCT06005532 · mabscale llc · Phase 3 · live · comparator · “Humira” · registered Jul 2023
  • NCT05640245 · MoonLake Immunotherapeutics AG · Phase 2 · comparator · “Adalimumab” · registered Nov 2022
  • NCT05637515 · Biocon Biologics Inc. · Phase 3 · comparator · “Humira 40 MG in Prefilled Syringe” · registered Nov 2022
  • NCT05510063 · Samsung Bioepis Co., Ltd. · Phase 4 · background · “Humira (Adalimumab)” · registered Aug 2022
Abbott41% of its industry studiesUS: Amgen (FDA 2016) + 3 othersEU: AbbVie (EMA 2003) + 10 others55 studies
deucravacitinibRecent, repeated
Evidence
  • NCT07724366 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Deucravacitinib tablets 6 mg” · registered Jul 2026
  • NCT07326813 · InventisBio Co., Ltd · Phase 3 · live · background · “BMS-986165 Tablet” · registered Dec 2025
  • NCT06973291 · Takeda · Phase 3 · comparator · “Deucravacitinib” · registered May 2025
  • NCT06220604 · Johnson & Johnson · Phase 3 · live · background · “Deucravacitinib” · registered Jan 2024
  • NCT06143878 · Johnson & Johnson · Phase 3 · live · background · “Deucravacitinib” · registered Nov 2023
Bristol-Myers Squibb98% of its industry studiesUS: Bristol-Myers Squibb (FDA 2022)EU: Bristol-Myers Squibb (EMA 2023)45 studies
UstekinumabRecent, repeated
Evidence
  • NCT07116967 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Ustekinumab” · registered Aug 2025
  • NCT06488664 · AO GENERIUM · Phase 3 · comparator · “Stelara®” · registered Jun 2024
  • NCT06425549 · UCB S.A. · Phase 3 · live · background · “ustekinumab” · registered May 2024
  • NCT05335356 · Biocon Biologics UK Ltd · Phase 3 · comparator · “Stelara” · registered Apr 2022
  • NCT04967508 · Samsung Bioepis Co., Ltd. · Phase 3 · background · “Stelara® (Ustekinumab)” · registered Jul 2021
Johnson & Johnson86% of its industry studiesUS: Johnson & Johnson (FDA 2009) + 7 othersEU: Johnson & Johnson (EMA 2009) + 11 others44 studies
secukinumabRecent, repeated
Evidence
  • NCT06945107 · Innovent Biologics, Inc. · Phase 3 · live · background · “Secukinumab” · registered Apr 2025
  • NCT06398652 · Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 3 · comparator · “Secukinumab” · registered May 2024
  • NCT06110676 · Joincare Pharmaceutical Group Industry Co., Ltd. · Phase 3 · live · comparator · “Secukinumab” · registered Oct 2023
  • NCT05377944 · Bio-Thera Solutions · Phase 3 · comparator · “EU-approved Cosentyx” · registered May 2022
  • NCT03536884 · UCB S.A. · Phase 3 · comparator · “Secukinumab” · registered May 2018
Novartis98% of its industry studiesUS: Novartis (FDA 2015)EU: Novartis (EMA 2015)44 studies
apremilastRecent, repeated
Evidence
  • NCT07712731 · Newsoara Biopharma Co., Ltd. · Phase 3 · comparator · “Apremilast” · registered Jul 2026
  • NCT06588738 · Alumis Inc · Phase 3 · comparator · “Apremilast” · registered Sep 2024
  • NCT06586112 · Alumis Inc · Phase 3 · comparator · “Apremilast” · registered Aug 2024
  • NCT06108544 · Takeda · Phase 3 · comparator · “Apremilast” · registered Oct 2023
  • NCT06088043 · Takeda · Phase 3 · comparator · “Apremilast” · registered Oct 2023
Amgen96% of its industry studiesUS: Amgen (FDA 2014)EU: off-patent, 1 generic authorized46 studies

13 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
RSS0393☆ Track1 live phase-3 study: NCT07543224Jiangsu HengRui Medicine Co., Ltd.
HS-20137☆ Track1 live phase-3 study: NCT06844799Hansoh Pharmaceutical Group Company Limited
SYHX1901☆ Track1 live phase-3 study: NCT06943950CSPC Pharmaceutical Group Limited
zasocitinib☆ Track3 live phase-3 studies: NCT07250802, NCT07752108, NCT06550076Takeda
D-2570☆ Track2 live phase-3 studies: NCT07326813, NCT07130604InventisBio Co., Ltd

The 5 in phase 3 with the nearest primary completion, of 63 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (20)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Dec 2026 est.HSK47388 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 main aimNCT07158268 A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis — primary endpoint: HSK47388 and Placebo Group: Percentage of Participants Achieving PASI 75 Response From Baseline to week 16 · 220 enrolled
  • 31 Dec 2026 est.SHR-1139 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07719530 Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis — primary endpoint: The proportion of participants who achieved a 100% improvement in the Psoriasis Area and Severity Index (PASI) score compared to the baseline by the 12th week (PASI 100). · 60 enrolled
  • Jan 2027 est.RSS0393 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 main aimNCT07543224 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. — primary endpoint: Achieving a Physician's Global Assessment (PGA) response at Week 8 · 600 enrolled

17 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Psoriasis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 11 open · Tyrosine kinase inhibitors (TKIs) 10 open · Antimetabolites 7 open · GLP-1 receptor agonists 3 open · Corticosteroids 2 open

Coming up

98studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger. 25 (14%) take children under 18. 4 (2%) are for women only and 0 (0%) for men only; 40 (23%) take healthy volunteers.

Recruiting studies that take each age, of 173
AgeWomenMen
1017 (10%)15 (9%)
18162 (94%)159 (92%)
30166 (96%)163 (94%)
40168 (97%)164 (95%)
50167 (97%)164 (95%)
65157 (91%)154 (89%)
75127 (73%)124 (72%)
85103 (60%)100 (58%)

Across all 2,030 studies, recruiting or not: 38% stop at 75 or younger and 21% at 65; 11% take children; 1% are for women only and 2% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Psoriasis studies take

Of 227 phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 110 mo5–17 · 155 studies10 mo4–16 · 137 studies—
Phase 1/29 mo3–21 · 15 studies——
Phase 214 mo9–23 · 175 studies12 mo9–20 · 146 studies36 mo20–43 · 29 studies
Phase 315 mo10–26 · 227 studies15 mo10–26 · 217 studies—
Phase 423 mo12–43 · 115 studies22 mo11–29 · 40 studies25 mo14–49 · 75 studies
Interventional, no phase19 mo8–38 · 134 studies—21 mo10–41 · 115 studies
Observational37 mo23–93 · 173 studies37 mo23–74 · 81 studies43 mo17–119 · 92 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,030. Browse all 2,030 → or search them.